4
|
Grubbs SS, Gonzalez M, Krasna M, Siegel R, Bryant D, Tschetter L, Hayenga L, Duggan B, St. Germaine D, Denicoff A. Tracking clinical trial accrual strategies and barriers via a Web-based screening tool. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6586] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6586 Background: The National Cancer Institute Community Cancer Centers Program (NCCCP) has developed a web based tracking tool to monitor screening of patients for clinical trial participation. The system is designed to collect data from multiple research sites throughout the geographically diverse group. The log blindly collects patient demographics, successful trial entry, and reasons for trial enrollment failure. Methods: Seven NCCCP sites utilized the log during the 60 day open accrual period for the Wake Forrest WFU 07–02–03 cancer control trial (chronic lymphocytic leukemia COLD- fX) in Novermber 2008 and December 2008. Results: 327 chronic lymphocytic leukemia patients were screened mostly by chart review. 162 (50%) were eligible for study entry. 45 (14%) entered the trial. 103 (31%) eligible patients declined entry. Of the 103, 72 (70%) did not wish to participate in research, 15 (15%) had travel constraints, 5 (5%) perceived excess toxicity, 9 (9%) gave no reason. 14 (3%) eligible had their physician decline entry. Overall, 28% of eligible patients entered the trial. 165 (50%) were trial ineligible. 82 (50%) for prior therapy, 30 (18%) for co morbid conditions, 10 (6%) missed an entry time requirement, 39 (24%) have incomplete data. Conclusions: The NCCCP trial screening log successfully captures real time clinical trial participation data from a diverse network of clinical trial sites. This data base will allow future analysis of individual clinical trial and site accrual barriers and empower strategies to increase trial participation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. S. Grubbs
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - M. Gonzalez
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - M. Krasna
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - R. Siegel
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - D. Bryant
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - L. Tschetter
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - L. Hayenga
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - B. Duggan
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - D. St. Germaine
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| | - A. Denicoff
- Helen F. Graham Cancer Center, Newark, DE; St. Joseph Hospital, Orange, CA; St. Joseph Medical Center, Towson, MD; Hartford Hospital, Hartford, CT; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA; Sanford USD Medical Center, Sioux Falls, SD; St. Vincent Indianapolis Hospital, Indianapolis, IN; NCI CBIIT Community Informatics Program, Rockville, MD; NCI Division of Cancer Prevention, Bethesda, MD; NCI CTEP, Bethesda, MD
| |
Collapse
|
5
|
Abstract
6048 Background: Single agent gemcitabine has been considered the standard of care in advanced pancreatic cancer since 1996. A recent 569 patient randomized trial comparing gemcitabine alone with gemcitabine + erlotinib as first line therapy found a small but statistically significant difference in survival (6.0 vs 6.4 months, respectively, p = .028). The impact on survival may be small, but with nearly 33,000 new cases of pancreatic cancer per year, the impact on health care costs with the use of the combined regimen may be large. Using the known survival data and costs, we analyzed the incremental cost-effectiveness of adding erlotinib. Methods: Costs for a six month course of gemcitabine were developed using Medicare reimbursement from the January, 2006 CMS Drug Payment Table and Physician Fee Schedule assuming no change in infusion reimbursement. Since erlotinib is not approved as a Medicare Part B drug, costs were developed from wholesale and retail sources. Drug dosing and schedules were based on the clinical trial protocol leading to approval. Incremental cost effectiveness of adding erlotinib was calculated. Results: Six month course of gemcitabine alone costs $23,493. The addition of erlotinib increases cost by $12,156 wholesale or $16,613 retail. Given an increase of 0.4 months in median survival over gemcitabine alone, the addition of erlotinib costs $364,680 per year of life gained (YLG) wholesale and $498,379/YLG retail. Sensitivity analyses were conducted assuming shorter therapy of 4 and 5 months. In order to be cost effective even at the $100,000/YLG level, six months of erlotinib would have to be reduced to 20% of the current retail cost (lowered to $18.52 per tablet.) Conclusions: Adding erlotinib to gemcitabine does not approach cost effectiveness at even the highest year per life gained parameters. Such impacts on health care costs, especially for very small gains, become more pressing as all health care costs continue to increase. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. S. Grubbs
- Helen F. Graham Cancer Center, Newark, DE; New York Lung Cancer Alliance, New York, NY
| | - P. A. Grusenmeyer
- Helen F. Graham Cancer Center, Newark, DE; New York Lung Cancer Alliance, New York, NY
| | - N. J. Petrelli
- Helen F. Graham Cancer Center, Newark, DE; New York Lung Cancer Alliance, New York, NY
| | - R. J. Gralla
- Helen F. Graham Cancer Center, Newark, DE; New York Lung Cancer Alliance, New York, NY
| |
Collapse
|
6
|
Guarino MJ, Masters GA, Schneider CJ, Biggs DD, Grubbs SS, Himelstein AL, Martin SE, Michaels LM, Guarino AJ, Rejtos L. Barriers exist to patient participation in clinical trials. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. J. Guarino
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - G. A. Masters
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - C. J. Schneider
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - D. D. Biggs
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - S. S. Grubbs
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - A. L. Himelstein
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - S. E. Martin
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - L. M. Michaels
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - A. J. Guarino
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| | - L. Rejtos
- HFGraham Cancer Ctr, Newark, DE; Drexel Univ, Philadelphia, PA; U Delaware, Newark, DE
| |
Collapse
|